BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 29802759)

  • 1. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
    Wong TT; Aung T; Ho CL
    Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
    Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
    Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
    Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
    Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension.
    Aptel F; Pfeiffer N; Schmickler S; Clarke J; Lavín-Dapena C; Moreno-Montañés J; Żarnowski T; Csutak A; Jugaste T; Volksone L; Astakhov YS; Coupier L; Nordmann JP; Stalmans I;
    J Glaucoma; 2019 Jun; 28(6):498-506. PubMed ID: 31166287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
    Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
    Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
    Ge J; Li X; Sun X; He X; Zhang H
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
    Kumagami T; Wakiyama H; Kusano M; Kajiyama A; Miura Y; Uematsu M; Yoneda A; Kurihara J; Suzuma K; Kitaoka T
    J Ocul Pharmacol Ther; 2014 May; 30(4):340-5. PubMed ID: 24576066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
    Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
    BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
    Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S;
    J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.
    Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
    Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
    Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
    Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
    Lopes JF; Hubatsch DA; Amaris P
    BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent].
    Mlčáková E; Mlčák P; Karhanová M; Langová K; Marešová K
    Cesk Slov Oftalmol; 2016; 72(4):120-127. PubMed ID: 27860477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues.
    El Ameen A; Vandermeer G; Khanna RK; Pisella PJ
    Eur J Ophthalmol; 2019 Nov; 29(6):645-653. PubMed ID: 30301370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study].
    Denis P;
    J Fr Ophtalmol; 2016 Sep; 39(7):622-30. PubMed ID: 27567675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
    Rolle T; Spinetta R; Nuzzi R
    BMC Ophthalmol; 2017 Aug; 17(1):136. PubMed ID: 28768500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
    Uusitalo H; Pillunat LE; Ropo A;
    Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.
    Aptel F; Choudhry R; Stalmans I
    Curr Med Res Opin; 2016 Aug; 32(8):1457-63. PubMed ID: 27310103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension.
    Suzuki K; Otsuka N; Hizaki H; Hashimoto M; Kuwayama Y;
    Adv Ther; 2018 Jun; 35(6):796-808. PubMed ID: 29873009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.